title: Atorvastatin decreases triacylglycerol-associated risk of vascular events in coronary heart disease patients.
abstract: High triacylglycerol (TAG) levels may predict vascular risk. The effect of a statin-induced reduction in TAG levels, irrespective of HDL-C increase, on clinical outcome has not yet been addressed by an endpoint study in patients with coronary heart disease (CHD). The GREACE study compared usual with structured care aimed at achieving LDL-C = 100 mg/dL (2.6 mmol/L) by dose titration with atorvastatin. All patients had CHD and were followed for 3 years. This post hoc analysis of GREACE examines the effect of statins on TAG levels and their relation with cardiovascular disease (CVD) events in all patients and in the subgroup of patients with metabolic syndrome (MetS). Baseline TAG levels >150 mg/dL (1.7 mmol/L) were predictive of subsequent CVD events [cardiac mortality, non-fatal myocardial infarction (MI), unstable angina (UA), revascularisation, congestive heart failure (CHF), and stroke] only in statin untreated patients. Stepwise regression analysis showed that with every 20% statin-related TAG reduction there was a decrease in CVD risk by 12% (HR 0.88, 95% CI 0.75-0.95, P = 0.007) in the structured care group vs. the usual care group, by 8% (HR 0.92, 95% CI 0.81-0.97, P = 0.02) in all statin treated patients vs. the untreated ones and by 15% (HR 0.85, 95% CI 0.65-0.94, P = 0.005) in those with MetS treated with a statin vs. those untreated. Using the same analysis but only taking into consideration vascular events (cardiac mortality, non-fatal MI, UA, revascularisation, and stroke) there was a 18% (HR = 0.82, 95% CI 0.57-0.96, P = 0.03) decrease in risk in the MetS (+) patients treated with a statin vs. those not on a statin, and a decrease in risk by 16% (HR = 0.84, 95% CI 0.53-1.07, P = 0.08), when only hard vascular endpoints (cardiac mortality, non-fatal MI, and stroke) were considered. TAG levels are predictive of subsequent CVD events in statin untreated CHD patients. Statin (mainly atorvastatin)-induced decrease in TAG levels was related to a significant reduction in subsequent CVD events. This benefit was more pronounced in CHD MetS (+) patients.
authors: Atherosclerosis and Metabolic Syndrome Units, 2nd Propedeutic Department of Internal Medicine, Aristotelian University, Hippocration Hospital, Thessaloniki, Greece.
authors: Vasilios G
authors: VG
authors: Athyros
authors: Anna I
authors: AI
authors: Kakafika
authors: Athanasios A
authors: AA
authors: Papageorgiou
authors: Konstantinos
authors: K
authors: Tziomalos
authors: Athanasios
authors: A
authors: Skaperdas
authors: Efstathios
authors: E
authors: Pagourelias
authors: Athina
authors: A
authors: Pirpasopoulou
authors: Asterios
authors: A
authors: Karagiannis
authors: Dimitri P
authors: DP
authors: Mikhailidis
mesh_terms: D000069059:Atorvastatin; D002318:Cardiovascular Diseases / Q000097:blood / Q000453:epidemiology / Q000517:prevention & control*; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D003327:Coronary Disease / Q000150:complications / Q000188:drug therapy*; D005215:Fasting; D005260:Female; D006538:Heptanoic Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D024821:Metabolic Syndrome / Q000097:blood / Q000150:complications; D008875:Middle Aged; D011758:Pyrroles / Q000008:administration & dosage / Q000627:therapeutic use*; D012044:Regression Analysis; D012307:Risk Factors; D014280:Triglycerides / Q000097:blood*
chemical_list: D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D006538:Heptanoic Acids; D011758:Pyrroles; D014280:Triglycerides; D000069059:Atorvastatin
references: Am J Kidney Dis. 2006 Mar;47(3):561; author reply 562
references: 16490637
references: J Am Coll Cardiol. 2005 Apr 5;45(7):1003-12
references: 15808755
references: Circulation. 2004 Jan 6;109(1):42-6
references: 14676144
references: Arterioscler Thromb Vasc Biol. 2001 Dec;21(12):2026-31
references: 11742880
references: J Cardiovasc Risk. 1996 Apr;3(2):213-9
references: 8836866
references: Am J Cardiol. 2004 Jan 15;93(2):136-41
references: 14715336
references: Am J Kidney Dis. 2004 Apr;43(4):589-99
references: 15042535
references: Circulation. 2006 May 16;113(19):2363-72
references: 16702489
references: Int J Cardiol. 2006 Mar 22;108(1):89-95
references: 16085325
references: Arterioscler Thromb Vasc Biol. 2000 Jan;20(1):189-97
references: 10634817
references: Expert Opin Biol Ther. 2007 Jan;7(1):53-72
references: 17150019
references: Curr Med Res Opin. 2002;18(4):220-8
references: 12201623
references: Coron Artery Dis. 1996 Nov;7(11):843-50
references: 8993943
references: Am J Cardiol. 2002 Oct 1;90(7):689-96
references: 12356379
references: Circulation. 2001 Dec 18;104(25):3046-51
references: 11748098
references: J Clin Pathol. 2004 Jul;57(7):728-34
references: 15220366
references: Atherosclerosis. 2003 Jun;168(2):397-8
references: 12801625
references: Am J Cardiol. 1992 Dec 14;70(19):10H-13H
references: 1466311
references: Diabetes Care. 2002 Jul;25(7):1198-202
references: 12087019
references: JAMA. 2001 May 16;285(19):2486-97
references: 11368702
references: N Engl J Med. 1999 Aug 5;341(6):410-8
references: 10438259
references: Diabetes Care. 2004 Jul;27(7):1735-40
references: 15220255
references: Curr Med Res Opin. 2006 Mar;22(3):511-28
references: 16574035
references: Am J Cardiol. 2002 Jul 15;90(2):139-43
references: 12106843
references: Curr Med Chem. 2005;12(17):1931-45
references: 16101498
references: N Engl J Med. 1993 Apr 29;328(17):1220-5
references: 8464432
references: Platelets. 2005 Mar;16(2):65-71
references: 15823861
references: Circulation. 2005 Oct 25;112(17):2735-52
references: 16157765
references: Circulation. 2004 Jul 13;110(2):227-39
references: 15249516
references: J Am Coll Cardiol. 2007 Jan 30;49(4):403-14
references: 17258085
references: Arterioscler Thromb Vasc Biol. 2005 Aug;25(8):1718-22
references: 15947240
references: Curr Drug Targets. 2007 Mar;8(3):483-8
references: 17348840
references: Curr Med Res Opin. 2004;20(2):241-7
references: 15006019
references: Am J Cardiol. 2004 Jan 1;93(1):31-9
references: 14697462
references: Am J Cardiol. 1998 Feb 26;81(4A):66B-69B
references: 9526817
references: Curr Med Res Opin. 2004 Sep;20(9):1385-92
references: 15383187
references: Circulation. 1992 Jan;85(1):37-45
references: 1728471
references: Metabolism. 2002 Mar;51(3):334-42
references: 11887170
references: Heart. 2005 Dec;91 Suppl 5:v1-52
references: 16365341
references: Curr Med Res Opin. 2003;19(6):540-56
references: 14594527
references: Am Heart J. 1986 Aug;112(2):432-7
references: 3739899
references: Lancet. 2005 Nov 26;366(9500):1849-61
references: 16310551
references: J Hum Hypertens. 2004 Nov;18(11):781-8
references: 15229622